Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Alligator Bioscience AB. (3/22/23). "Press Release: Alligator Intends to Carry Out a 91 Percent Secured Rights Issue of Units of Approximately SEK 199 Million [Not for US, AU, et al.]".

Organisations Organisation Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
  Group Alligator Bioscience (Group)
  Organisation 2 Redeye AB
Products Product ALG.APV-527 (Alligator Bioscience / Aptevo Therapeutics)
  Product 2 mitazalimab (ADC-1013)
Index term Index term Alligator Bioscience–SEVERAL: investment, 202303– rights issue up to SEK199m shares plus up to approx SEK22m warrants, if exercised
Person Person Bregenholt, Søren (Alligator Bioscience 202106– CEO before Macrophage Pharma + Novo Nordisk + Symphogen)
     


   
Record changed: 2024-01-20

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Alligator Bioscience (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top